Dermatomyositis is a rare, chronic, inflammatory myopathy characterized by progressive muscle weakness and distinctive skin rashes, often associated with autoimmune mechanisms. It can occur in ...

The dermatomyositis market is expected to witness steady growth over the next decade, driven by increasing awareness, improved diagnostic tools, and advancements in treatment options. The rising ...

More information: Margaux Saillard et al, Engineered CD4 TCR-T Cells with Conserved High-Affinity TCRs Targeting NY-ESO-1 for Advanced Cellular Therapies in Cancer, Science Advances (2025).

Low levels of either increase the likelihood of infections and other health problems. HIV itself can reduce CD4 count – a value lower than 200 indicates acquired immunodeficiency syndrome (AIDS).

Ovarian cancer coexisting with dermatomyositis is well recognized, [1, 2] and more often than not the latter precedes the malignancy by months to years. [2] ...

CD4-positive T cells are a subtype of lymphocyte. They are MHC class II-restricted and are important mediators of adaptive immunity. These cells are involved in both the induction and the ...

Just a few months after announcing a plan to separate its drug and cell therapy businesses into two separate companies, Belgian biotech Galapagos has had a change of heart – and a change of ...

The plan is to stop working on small-molecule drugs, including TYK2 inhibitor GLPG3667, which is in phase 2 trials for systemic lupus erythematosus (SLE) and dermatomyositis, and seek development ...

Keywords: ruxolitinib, dermatomyositis, essential thrombocytosis, JAK2 V617F mutation, anti-TIF1γ antibody Citation: Jing X, Min W, Xia L and Shanshan L (2025) Ruxolitinib in adult dermatomyositis ...

A novel helper role for CD4 T cellsAPC are bone marrow-derived cells with the ability to induce primary immune responses. One of the most potent types of APC is the dendritic cell (DC). DC pick up ...